KMDA News & Events

Kamada announced that, based on its positive outlook for 2026, it is forecasting continued double-digit profitable growth with 2026 annual guidance of $200M - $205M in revenues and $50M - $53M of adjusted EBITDA. Importantly, the projected 2026 growth is based solely on continued organic growth of the Company's diverse commercial products portfolio in multiple markets in both its Proprietary segment which covers the specialty plasma therapies and the Distribution segment which covers commercialization of in-licensing third parties biopharmaceutical products. The 2026 midpoint guidance range represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA, based on the mid-points of Kamada's 2025 guidance. The Company further announced that it expects to achieve its 2025 financial guidance of $178M - $182M in revenues and $40M - $44M of adjusted EBITDA, with 2025 year-end cash of approximately $75M. Kamada intends to publish its 2025 financial results during the first half of March 2026. "We enter 2026 from a position of significant commercial and financial strength and are excited about the progress we have made over the past year," said Amir London, CEO. "We look forward to achieving our value generating objectives for 2026, driven by continued organic growth of our diverse commercial product portfolio marketed in over 30 countries. We are also pleased with our ability to consistently convert adjusted EBITDA into operational cash." Our projected growth in 2026 is expected to be driven by continued expansion of our entire commercial product portfolio, including growth in our U.S. sales, and continued increase in sales of KAMRAB, GLASSIA, HEPAGAM and VARIZIG in ex-U.S. markets. We also anticipate continued growth of our Distribution segment through the launch of additional biosimilar products in the Israeli market, as well as the expansion of the Distribution business to the MENA region, and initial sales of normal source plasma collected in our multiple centers in Texas. The overall profitable growth is achievable even after accounting for a reduction of the GLASSIA royalty payments rate received from TAKEDA, which became effective in August 2025 and will have its first full-year impact in 2026, further solidifying the strength of our diverse commercial infrastructure. We also continue to focus on identifying and securing compelling new business development and M&A transactions. We expect that these initiatives will enrich our current portfolio of marketed products and generate synergies with our existing commercial operations. In addition, we expect to continue increasing the plasma collection in our three plasma centers aiming to strengthen our vertical integration, reduce specialty plasma costs and support continued growth through sales of normal source plasma."

The major averages were broadly higher near noon as investors react to the release of the delayed November Consumer Price Index inflation report and other key economic data. Traders are closely watching not only CPI but also jobless claims and regional manufacturing surveys, all of which could influence how the Federal Reserve views inflation and growth heading into 2026.Globally, other central banks are making moves as well. Just a week after the U.S. Federal Reserve cut its federal funds rate, the Bank of England lowered its Bank rate by 0.25 percentage points. The European Central Bank, however, maintained its three key interest rates, saying that its updated assessment reconfirms that inflation should stabilize at the 2% target in the medium term.Looking to commodities, gold hit new a new record high, with the "safe haven" asset hovering around the $4,400 mark. Oil prices were also surging as the commodity rebounds from sharp declines this week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Micronreportedand provided upbeat Q2 earnings and revenue guidanceTrump Mediawith TAE Technologies in an over $6B transactionElliott has built a position of over $1B in Lululemon,Dardenreportedand reiterated its FY26 outlookThe Bank of Englandby 0.25 percentage points to 3.75%, while the European Central Bank kept its three key interest rates unchanged2. WALL STREET CALLS:Merckto Outperform at BMO CapitalPayPalto Underweight at Morgan StanleyRivianto Outperform at BairdJefferiesGE Vernovaon gas pricing, services visibilityLennarto Underperform at RBC Capital, Evercore ISI and BofA after weaker than anticipated fiscal Q4 results and Q1 guidance3. AROUND THE WEB:Over three dozen state attorneys general are urging Metato strengthen enforcement of its policies against misleading weight loss drug ads on Instagram and Facebook, including AI-generated content,Appleis in preliminary talks with India-based CG Semi, which offers chip assembly and testing services, to assemble and package chips for the iPhone,Googleis suing Darcula, a Chinese-speaking cybercriminal group, claiming it is responsible for a massive amount of scam text messages sent to Americans over the past year,Warner Bros.urged its shareholders to reject Paramount Skydance'shostile takeover bid, arguing Paramount was inadequate compared to Netflix,The U.S. Federal Trade Commission is investigating Instacartas the retail platform grapples with criticism of its AI-powered pricing tool,4. MOVERS:Sable Offshoreincreases after the U.S. DOT'sthe company's pipeline connecting the Santa Ynez Unit to the Pentland Station terminal in Kern County, California is an interstate pipeline facilityRedwiregains after announcing it will provide two International Docking System Standardfor The Exploration Company's spacecraftFuelCellhigher after, with EPS higher year-over-yearInsmedfalls after announcing its Phase 2bdid not meet its primary or secondary endpointBirkenstocklower in New York afterand providing guidance for FY265. EARNINGS/GUIDANCE:Accentureand backed its guidance for FY26CarMax, with EPS and revenue beating consensusCintasand raised its guidance for FY26FactSet, with CEO Sanoke Viswanathan commenting, "FactSet's strong start to the year underscores the quality of our data and products"Kamadafor FY25INDEXES:Near midday, the Dow was up 0.65%, or 312.84, to 48,198.81, the Nasdaq was up 1.92%, or 436.13, to 23,129.46, and the S&P 500 was up 1.24%, or 83.34, to 6,804.77.

Kamada has been awarded an extension of an existing tender from the Canadian Blood Services for the supply of four specialty plasma-derived products, WINRHO, HEPAGAM, CYTOGAM, and VARIZIG, for an additional two years. Valued at a range of $10M-$14M, the award secures ongoing sales of those products in the Canadian market between Q2-26 and Q1-28. The four commercial products are approved by Health Canada and the U.S. Food and Drug Administration. CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec.

"This award extension, together with continued supply of KAMRAB, our anti-Rabies Immunoglobulin product used in Canada, and GLASSIA, our AAT product licensed to Takeda for distribution in Canada, validates our position as the leading supplier of specialty plasma derived products in Canada," said Amir London, Kamada's CEO. "We remain confident that significant commercial potential exists for our AAT and specialty immunoglobulin portfolio in the international markets and intend to continue pursuing additional contracts in key strategic territories." As recently stated, based on our strong, consistent performance during 2025, we have reiterated our full-year 2025 revenue guidance of between $178M to $182M and our annual adjusted EBITDA guidance of $40M to $44M. Additionally, we project double-digit growth in revenues and profitability in 2026 through our robust commercial portfolio, growing biosimilar portfolio in Israel, and the expansion of normal source plasma sales. In parallel, we continue to focus on pursuing new commercial stage business development opportunities, leveraging our strong cash position, to support continued long-term growth," concluded Mr. London.